Condition: BAG3 Mutation Associated Dilated Cardiomyopathy · Sponsor: Alexion Pharmaceuticals, Inc.
This Phase 1/2 study is an open-label, dose finding and dose expansion study investigating the safety, tolerability, and efficacy of a single IV infusion of ALXN2350 in adult participants with BAG3 associated DCM.
This description comes directly from the study's public registry record.
Alexion Pharmaceuticals, Inc. (Sponsor) · 1-855-752-2356 · clinicaltrials@alexion.com
Always discuss trial participation with your own doctor first.
| Research Site | Birmingham, Alabama, United States | Recruiting |
| Research Site | Boston, Massachusetts, United States | Recruiting |
| Research Site | Cincinnati, Ohio, United States | Recruiting |
| Research Site | Portland, Oregon, United States | Recruiting |
| Research Site | Philadelphia, Pennsylvania, United States | Recruiting |
| Research Site | Houston, Texas, United States | Recruiting |
| Research Site | Massa, Italy | Recruiting |
| Research Site | Barcelona, Spain | Recruiting |
| Research Site | Majadahonda, Spain | Recruiting |
| Research Site | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07218887